What dose of CagriSema is used and how is it given?
Every vial at a glance.
| Vial | 3 mL of water |
|---|---|
| 9.6 mg | 3.2 mg/mL: 0.25 mg is 7.8 units, 0.5 mg is 15.6 units, 1 mg is 31.3 units, 1.7 mg is 53.1 units, 2.4 mg is 75 units |
No CagriSema label was located and Novo Nordisk calls it investigational,1 so the doses here are trial doses, such as cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly, reached from 0.25 mg once weekly in 4-week steps in the 32-week phase 2 trial of Frias and colleagues (2023) in 92 adults with type 2 diabetes.23
What form CagriSema comes in
None of the sources retrieved gives a CagriSema vial strength, concentration, pen volume or mixing instruction. The 9.6 mg in 3 mL (3.2 mg/mL) behind the table above is the Wegovy FlexTouch pen, a semaglutide-alone label figure, so the rows are arithmetic and not a CagriSema strength.4
| Form | What the sources say |
|---|---|
| Solution for injection | The EMA's paediatric record for cagrilintide with semaglutide lists it, given subcutaneously5 |
| Pen-injector | A Novo Nordisk crossover study names two pen-injectors, DV3384 and PDS2906 |
| Powder or vial | Not stated in the sources retrieved |
The FDA says unfamiliarity with drawing from a vial, with confusion between milliliters, milligrams and "units", may have contributed to dosing errors with compounded semaglutide, and a "unit" volume may vary with concentration.7 The mixing guide and the CagriSema calculator show general vial arithmetic only.
Is there a CagriSema label?
Novo Nordisk describes CagriSema 2.4 mg/2.4 mg as an investigational fixed-dose injectable medicine.1 On 18 Dec 2025 it announced the submission of a New Drug Application to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection in adults with obesity, or with overweight and at least one weight-related comorbid condition.1 No FDA decision on the application was among the sources retrieved.
CagriSema doses and schedule in trials
Each trial in the table gave cagrilintide with semaglutide, or a comparator, subcutaneously once weekly, and the trials differ in dose, escalation and length.892101112
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| REDEFINE 1 (Garvey, 2025) | Cagrilintide 2.4 mg with semaglutide 2.4 mg after a 16-week dose escalation, against semaglutide 2.4 mg, cagrilintide 2.4 mg or placebo13814 | 3417 adults without diabetes: 2108 on cagrilintide-semaglutide, 302 on semaglutide, 302 on cagrilintide, 705 on placebo13 | 68 weeks13 |
| REDEFINE 2 (Davies, 2025) | Cagrilintide-semaglutide 2.4 mg each, or placebo, assigned 3:115 | 1206 adults with type 2 diabetes: 904 on cagrilintide-semaglutide, 302 on placebo15 | 68 weeks15 |
| Phase 2 (Frias, 2023) | 0.25 mg once weekly, then 0.5, 1.0 and 1.7 mg at 4-week steps, to 2.4 mg of each from week 17 to week 32, against semaglutide or cagrilintide alone23 | 92 adults with type 2 diabetes: 31 on CagriSema, 31 on semaglutide, 30 on cagrilintide2 | 32 weeks3 |
| Phase 1b (Enebo, 2021) | Cagrilintide 0.16 to 4.5 mg or matched placebo (3:1), each with semaglutide 2.4 mg, co-escalated in 4-week intervals10 | 96 randomised people aged 18 to 55 with a body-mass index of 27.0 to 39.9 who were otherwise healthy, at a single centre in the USA10 | 16 weeks escalation, 4 at target, 5 follow-up10 |
| REDEFINE 9, phase 3b (Wharton, 2026) | Cagrilintide-semaglutide 1.7 mg each (escalated from 0.25 mg each over 12 weeks) or 1.0 mg each (over 8 weeks), or placebo1116 | 309 randomised adults without diabetes: 104 on 1.7 mg each, 103 on 1.0 mg each, 102 on pooled placebo11 | 68 weeks11 |
| REDEFINE 5 (Yamauchi, 2026) | Cagrilintide-semaglutide or semaglutide alone (1:1), both escalated to 2.4 mg12 | 331 adults in Japan and Taiwan, with or without type 2 diabetes: 164 on cagrilintide-semaglutide, 167 on semaglutide12 | 68 weeks12 |
What the semaglutide label says
Novo Nordisk describes CagriSema as cagrilintide 2.4 mg with semaglutide 2.4 mg,1 while the Wegovy label covers semaglutide alone, in single-dose pens of 0.25 mg/0.5 mL up to 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (Wegovy HD), and in a FlexTouch pen of 9.6 mg/3 mL (3.2 mg/mL) that delivers four 2.4 mg/0.75 mL doses.4 Its Table 1, for all approved indications in adults and pediatric patients aged 12 years and older, starts at 0.25 mg once weekly for 4 weeks, then escalates every 4 weeks.4 After escalation, the label gives a usual maintenance dosage of 2.4 mg once weekly and, for weight reduction in adults, either 1.7 mg or 2.4 mg once weekly, with an increase to a maximum of 7.2 mg once weekly for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated; it also says escalation may be delayed for 4 weeks if a dose is not tolerated.4
How CagriSema is stored
The sources retrieved give no CagriSema storage statement, before or after first use. The Wegovy label (semaglutide alone) stores the single-dose pen or syringe at 2°C to 8°C in the original carton, protected from light; if needed, before cap removal, the pen can be kept at 8°C to 30°C for up to 28 days.4
Frequently asked questions
Where is CagriSema injected?
The EMA's record lists the route as subcutaneous use.5 The sources retrieved give no CagriSema injection site statement.
Can CagriSema be compounded from powder?
The FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of FDA-approved drugs.17
References
- Novo Nordisk (press release via BioSpace). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. 2025. biospace.com
- Lancet (London, England) (PubMed abstract). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. 2023. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT04982575: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes. 2023. clinicaltrials.gov
- Novo Nordisk Pharmaceutical Industries, LP via DailyMed (US label). WEGOVY (semaglutide) injection and tablets, US prescribing information. 2026. dailymed.nlm.nih.gov
- European Medicines Agency. EMA/PE/0000240529 - paediatric investigation plan | European Medicines Agency (EMA). 2026. ema.europa.eu
- ClinicalTrials.gov (US National Library of Medicine). NCT06716307: A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity. 2025. clinicaltrials.gov
- US FDA. FDA alerts health care providers, compounders of dosing errors. 2024. fda.gov
- Hypertension (Dallas, Tex. : 1979) (full text, PubMed Central). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. 2025. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT05394519: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight. 2025. clinicaltrials.gov
- Lancet (London, England) (PubMed abstract). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. 2021. pubmed.ncbi.nlm.nih.gov
- The lancet. Diabetes & endocrinology (PubMed abstract). Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9). 2026. pubmed.ncbi.nlm.nih.gov
- The lancet. Diabetes & endocrinology (PubMed abstract). Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5). 2026. pubmed.ncbi.nlm.nih.gov
- The New England journal of medicine (PubMed abstract). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
- The New England journal of medicine (PubMed abstract). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT06388187: A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
- US FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. fda.gov